AP Biosciences, Inc. (TPEX:6945)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
187.00
-3.50 (-1.84%)
Apr 28, 2026, 1:56 PM CST
314.17%
Market Cap 15.96B
Revenue (ttm) n/a
Net Income (ttm) -444.77M
Shares Out 85.57M
EPS (ttm) -5.23
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 595,024
Average Volume 591,807
Open 190.50
Previous Close 190.50
Day's Range 184.00 - 191.00
52-Week Range 45.25 - 236.00
Beta -0.01
RSI 45.18
Earnings Date May 12, 2026

About AP Biosciences

AP Biosciences, Inc. researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal squamous-cell carcinomas; AP402, which is in the pre-clinical research phase for breast cancer patients; and AP601 that is in pre-clinic... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2013
Employees 37
Stock Exchange Taipei Exchange
Ticker Symbol 6945
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.